Bacitracin E
| Internal ID | e14601e8-0652-4ab7-93c1-001f0456c917 |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Hybrid peptides |
| IUPAC Name | (4R)-4-[[(2S)-2-[[(4R)-2-[(1S)-1-amino-2-methylpropyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[4-[(2S,5R,8S,11R,14S,17R,20S)-20-(2-amino-2-oxoethyl)-5-(3-aminopropyl)-11-benzyl-17-(carboxymethyl)-14-(1H-imidazol-5-ylmethyl)-3,6,9,12,15,18,21-heptaoxo-8-propan-2-yl-1,4,7,10,13,16,19-heptazacyclohenicos-2-yl]butylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C63H97N17O16S/c1-31(2)23-40(73-60(94)45-29-97-63(78-45)49(66)32(3)4)55(89)72-39(19-20-47(82)83)54(88)79-50(33(5)6)61(95)68-22-13-12-17-37-52(86)70-38(18-14-21-64)53(87)80-51(34(7)8)62(96)77-41(24-35-15-10-9-11-16-35)56(90)74-42(25-36-28-67-30-69-36)57(91)76-44(27-48(84)85)59(93)75-43(26-46(65)81)58(92)71-37/h9-11,15-16,28,30-34,37-45,49-51H,12-14,17-27,29,64,66H2,1-8H3,(H2,65,81)(H,67,69)(H,68,95)(H,70,86)(H,71,92)(H,72,89)(H,73,94)(H,74,90)(H,75,93)(H,76,91)(H,77,96)(H,79,88)(H,80,87)(H,82,83)(H,84,85)/t37-,38+,39+,40-,41+,42-,43-,44+,45-,49-,50-,51-/m0/s1 |
| InChI Key | ZJMVHDNOCAUOCL-GMSINAEZSA-N |
| Popularity | 0 references in papers |
| Molecular Formula | C63H97N17O16S |
| Molecular Weight | 1380.60 g/mol |
| Exact Mass | 1379.70199125 g/mol |
| Topological Polar Surface Area (TPSA) | 556.00 Ų |
| XlogP | -5.20 |
| Atomic LogP (AlogP) | -2.85 |
| H-Bond Acceptor | 19 |
| H-Bond Donor | 17 |
| Rotatable Bonds | 32 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | - | 0.5425 | 54.25% |
| Caco-2 | - | 0.8645 | 86.45% |
| Blood Brain Barrier | - | 0.9250 | 92.50% |
| Human oral bioavailability | - | 0.5000 | 50.00% |
| Subcellular localzation | Mitochondria | 0.4972 | 49.72% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.8732 | 87.32% |
| OATP1B3 inhibitior | + | 0.9458 | 94.58% |
| MATE1 inhibitior | - | 0.9209 | 92.09% |
| OCT2 inhibitior | - | 0.8500 | 85.00% |
| BSEP inhibitior | + | 0.9696 | 96.96% |
| P-glycoprotein inhibitior | + | 0.7421 | 74.21% |
| P-glycoprotein substrate | + | 0.8958 | 89.58% |
| CYP3A4 substrate | + | 0.7397 | 73.97% |
| CYP2C9 substrate | - | 0.8067 | 80.67% |
| CYP2D6 substrate | - | 0.8493 | 84.93% |
| CYP3A4 inhibition | - | 0.9510 | 95.10% |
| CYP2C9 inhibition | - | 0.8956 | 89.56% |
| CYP2C19 inhibition | - | 0.8758 | 87.58% |
| CYP2D6 inhibition | - | 0.9277 | 92.77% |
| CYP1A2 inhibition | - | 0.8628 | 86.28% |
| CYP2C8 inhibition | + | 0.7930 | 79.30% |
| CYP inhibitory promiscuity | - | 0.9115 | 91.15% |
| UGT catelyzed | - | 0.0000 | 0.00% |
| Carcinogenicity (binary) | - | 0.8700 | 87.00% |
| Carcinogenicity (trinary) | Non-required | 0.6107 | 61.07% |
| Eye corrosion | - | 0.9865 | 98.65% |
| Eye irritation | - | 0.8958 | 89.58% |
| Skin irritation | - | 0.7750 | 77.50% |
| Skin corrosion | - | 0.9246 | 92.46% |
| Ames mutagenesis | - | 0.7100 | 71.00% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7066 | 70.66% |
| Micronuclear | + | 0.6800 | 68.00% |
| Hepatotoxicity | + | 0.7250 | 72.50% |
| skin sensitisation | - | 0.8344 | 83.44% |
| Respiratory toxicity | + | 0.8444 | 84.44% |
| Reproductive toxicity | + | 0.9484 | 94.84% |
| Mitochondrial toxicity | + | 0.8500 | 85.00% |
| Nephrotoxicity | - | 0.6577 | 65.77% |
| Acute Oral Toxicity (c) | III | 0.5936 | 59.36% |
| Estrogen receptor binding | + | 0.5349 | 53.49% |
| Androgen receptor binding | + | 0.7156 | 71.56% |
| Thyroid receptor binding | + | 0.7496 | 74.96% |
| Glucocorticoid receptor binding | + | 0.8022 | 80.22% |
| Aromatase binding | + | 0.7987 | 79.87% |
| PPAR gamma | + | 0.7526 | 75.26% |
| Honey bee toxicity | - | 0.7044 | 70.44% |
| Biodegradation | - | 0.8750 | 87.50% |
| Crustacea aquatic toxicity | - | 0.5000 | 50.00% |
| Fish aquatic toxicity | + | 0.7712 | 77.12% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL2581 | P07339 | Cathepsin D | 99.86% | 98.95% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 99.52% | 96.09% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 98.92% | 90.17% |
| CHEMBL1907594 | P30926 | Neuronal acetylcholine receptor; alpha3/beta4 | 98.86% | 97.23% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 98.42% | 97.64% |
| CHEMBL1795139 | Q8IU80 | Transmembrane protease serine 6 | 97.58% | 98.33% |
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 97.46% | 83.82% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 97.23% | 91.11% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 97.01% | 94.45% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 96.77% | 90.08% |
| CHEMBL2492 | P36544 | Neuronal acetylcholine receptor protein alpha-7 subunit | 96.68% | 88.42% |
| CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 95.68% | 85.14% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 95.34% | 96.90% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 95.28% | 93.00% |
| CHEMBL220 | P22303 | Acetylcholinesterase | 95.10% | 94.45% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 94.71% | 95.56% |
| CHEMBL1293287 | P14735 | Insulin-degrading enzyme | 94.09% | 88.10% |
| CHEMBL4462 | Q8IXJ6 | NAD-dependent deacetylase sirtuin 2 | 94.00% | 90.24% |
| CHEMBL1255126 | O15151 | Protein Mdm4 | 93.30% | 90.20% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 93.24% | 99.17% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 92.68% | 95.00% |
| CHEMBL202 | P00374 | Dihydrofolate reductase | 92.19% | 89.92% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 91.88% | 100.00% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 90.80% | 100.00% |
| CHEMBL4018 | P49146 | Neuropeptide Y receptor type 2 | 90.06% | 98.94% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 89.43% | 97.09% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 89.33% | 98.05% |
| CHEMBL4777 | P25929 | Neuropeptide Y receptor type 1 | 89.21% | 96.67% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 89.21% | 95.71% |
| CHEMBL3891 | P07384 | Calpain 1 | 88.96% | 93.04% |
| CHEMBL3091268 | Q92753 | Nuclear receptor ROR-beta | 88.79% | 95.50% |
| CHEMBL3492 | P49721 | Proteasome Macropain subunit | 88.77% | 90.24% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 88.53% | 93.56% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 88.02% | 88.56% |
| CHEMBL2179 | P04062 | Beta-glucocerebrosidase | 88.00% | 85.31% |
| CHEMBL1907600 | Q00535 | Cyclin-dependent kinase 5/CDK5 activator 1 | 86.12% | 93.03% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 86.09% | 96.47% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 85.66% | 98.59% |
| CHEMBL5028 | O14672 | ADAM10 | 85.57% | 97.50% |
| CHEMBL1907591 | P30926 | Neuronal acetylcholine receptor; alpha4/beta4 | 85.50% | 100.00% |
| CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 84.98% | 96.00% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 84.84% | 92.32% |
| CHEMBL3830 | Q2M2I8 | Adaptor-associated kinase | 84.30% | 83.10% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 84.06% | 90.71% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 83.75% | 97.14% |
| CHEMBL1781 | P11387 | DNA topoisomerase I | 83.74% | 97.00% |
| CHEMBL3776 | Q14790 | Caspase-8 | 83.71% | 97.06% |
| CHEMBL2535 | P11166 | Glucose transporter | 83.05% | 98.75% |
| CHEMBL3468 | P55210 | Caspase-7 | 82.85% | 95.68% |
| CHEMBL1628481 | P35414 | Apelin receptor | 82.71% | 97.89% |
| CHEMBL1744525 | P43490 | Nicotinamide phosphoribosyltransferase | 82.07% | 96.25% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 82.03% | 95.89% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 81.85% | 99.23% |
| CHEMBL2208 | P49137 | MAP kinase-activated protein kinase 2 | 81.72% | 95.20% |
| CHEMBL3401 | O75469 | Pregnane X receptor | 81.35% | 94.73% |
| CHEMBL4101 | P17612 | cAMP-dependent protein kinase alpha-catalytic subunit | 81.29% | 82.86% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 81.15% | 95.89% |
| CHEMBL4071 | P08311 | Cathepsin G | 80.95% | 94.64% |
| CHEMBL3837 | P07711 | Cathepsin L | 80.84% | 96.61% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 80.60% | 96.11% |
| CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 80.29% | 82.38% |
| CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 80.03% | 89.34% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 139587956 |
| LOTUS | LTS0256009 |
| wikiData | Q105377981 |